The Impact of Systemic Therapy Beyond First-line Treatment for Advanced Cervical Cancer

详细信息    查看全文

• 作者：J. McLachlan^&lowast ; ; S. Boussios^&lowast ; ; A. Okines^&lowast ; ; D. Glaessgen^&lowast ; ; S. Bodlar^&dagger ; ; R. Kalaitzaki^&dagger ; ; A. Taylor^&lowast ; ; S. Lalondrelle^&lowast ; ; M. Gore^&lowast ; ; S. Kaye^&lowast ; ; S. Banerjee^&Dagger ; ; ^{susana.banerjee@rmh.nhs.uk}
• 关键词：Cervical cancer ; chemotherapy ; metastatic ; second-line ; targeted therapy
• 刊名：Clinical Oncology
• 出版年：2017
• 出版时间：March 2017
• 年：2017
• 卷：29
• 期：3
• 页码：153-160
• 全文大小：364 K
• 卷排序：29

文摘

There is no standard of care for second-line systemic therapy for advanced cervical cancer. The objective response rate to second-line systemic therapy in this study was low, < 15%. Patients should be considered for clinical trials, including novel targeted agents and immunotherapy.